Cited by 1,065HIV-related health complications and treatmentsLipid metabolism and disordersPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Carr, Andrew, Samaras, Katherine, Chisholm, Donald J, Cooper, David A·1998·The Lancet

DOI 10.1016/s0140-6736(98)03391-1

Open this paper in CoChat — free account

Abstract

HIV-1 protease-inhibitor treatments are associated with a syndrome of peripheral lipodystrophy, central adiposity, breast hypertrophy in women, hyperlipidaemia, and insulin resistance. The catalytic region of HIV-1 protease, to which protease inhibitors bind, has approximately 60% homology to regions within two proteins that regulate lipid metabolism: cytoplasmic retinoic-acid binding protein type 1 (CRABP-1) and low density lipoprotein-receptor-related protein (LRP). We hypothesise that protease inhibitors inhibit CRABP-1-modified, and cytochrome P450 3A-mediated synthesis of cis-9-retinoic acid, a key activator of the retinoid X receptor; and peroxisome proliferator activated receptor type gamma (PPAR-gamma) heterodimer, an adipocyte receptor that regulates peripheral adipocyte differentiation and apoptosis. Protease-inhibitor binding to LRP would impair hepatic chylomicron uptake and triglyceride clearance by the endothelial LRP-lipoprotein lipase complex. The resulting hyperlipidaemia contributes to central fat deposition (and in the breasts in the presence of oestrogen), insulin resistance, and, in susceptible individuals, type 2 diabetes. Understanding the syndrome's pathogenesis should lead to treatment strategies and to the design of protease inhibitors that do not cause this syndrome.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(98)03391-1

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,564
A decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
FORMAN, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,857
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
Carr, A., Samaras, K., Burton, S., Law, M. G., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,364
Self-citation
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
Navia, M. A., Fitzgerald, P. M. D., McKeever, B. M., Leu, C., Heimbach, J. C., Herber, W. K., Sigal, I. S., Darke, P. L., & Springer, J. P. (1989) · Nature · doi:10.1038/337615a0 · Cited by 892
Visceral abdominal-fat accumulation associated with use of indinavir
Miller, K. D., Jones, E. C., Yanovski, J. A., Shankar, R., Feuerstein, I. M., & Falloon, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11518-5 · Cited by 697
The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein
Beisiegel†, U., Weber, W. T., Ihrke, G., Herz, J., & Stanley, K. K. (1989) · Nature · doi:10.1038/341162a0 · Cited by 680
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
Mukherjee, R., Davies, P. J., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., et al. (1997) · Nature · doi:10.1038/386407a0 · Cited by 601

Show all 24 references

Research works printed but not linked: 1

Despres, 1995, The insulin-resistance-dysipidemic syndrome: contributioin of visceral obesity and therapeutic implications, Int J Obesity, 19, S76

Sorted by citations

Items 501–600 of 1,000

Visceral obesity, hypertriglyceridemia and hypercortisolism in a boy with perinatally acquired HIV infection receiving protease inhibitor-containing antiviral treatment
Arpadi, S. M., Cuff, P. A., Horlick, M. N. B., & Kotler, D. P. (1999) · AIDS · doi:10.1097/00002030-199911120-00020 · Cited by 22
Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance
Freitas, P., Carvalho, D. M., Santos, A. C., Mesquita, J., Matos, M. J., Madureira, A. J., Martínez, E., Sarmento, A., & Medina, J. L. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-180 · Cited by 21
An observational study of the prevalence of metabolic syndrome in treatment-experienced people living with HIV in Singapore
Ang, L. W., Ng, O. T., Boudville, I. C., Leo, Y., & Wong, C. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252320 · Cited by 21
Ultrasonographic Measurement of Intra-Abdominal Fat Thickness in HIV-Infected Patients Treated or Not with Antiretroviral Drugs and Its Correlation to Lipid and Glycemic Profiles
Guimarães, M. M. M., Júnior, A. R. D. O., Penido, M. G., de Queiróz, L. C., Goulart, E. M. A., Greco, D. B., & Machado, L. J. D. C. (2007) · Annals of Nutrition and Metabolism · doi:10.1159/000100819 · Cited by 21
Prevalence and factors associated with dry skin in HIV infection: the FRAM study
Lee, D., Benson, C. A., Lewis, C. E., Grünfeld, C., & Scherzer, R. (2007) · AIDS · doi:10.1097/qad.0b013e3282eea51a · Cited by 21
“This inhibition may alter or disrupt the normal metabolism of retinoic acid, because cytochrome P450 3A enzymes are known to mediate the synthesis of retinoic acid [22].”
Background
Endothelial dysfunction in HIV infection
Cotter, B. R. (2006) · Current HIV/AIDS Reports · doi:10.1007/bf02696656 · Cited by 21
Paronychia in Association with Indinavir Treatment
Colson, A. E., Sax, P. E., Keller, M. J., Turk, B. K., Pettus, P. T., Platt, R., & Choo, P. W. (2001) · Clinical Infectious Diseases · doi:10.1086/317546 · Cited by 21
“been postulated to play a role in the syndrome of peripheral fat lipoatrophy seen in PI recipients [9].”
Background
Generalized hair loss induced by indinavir plus ritonavir therapy
Ginarte, M., Losada, E., Prieto, A., Lorenzo‐Zúñiga, V., & Toribio, J. (2002) · AIDS · doi:10.1097/00002030-200208160-00021 · Cited by 21
Ingrown toenail and indinavir: case-control study demonstrates strong relationship
Bourezane, Y., Thalamy, B., Viel, J., Bardonnet, K., Drobacheff, C., Gil, H., Vuitton, D. A., & Hoen, B. (1999) · AIDS · doi:10.1097/00002030-199910220-00030 · Cited by 21
HIV-associated Lipodystrophy Syndrome: Description and Pathogenesis
Bodasing, N., & Fox, R. (2003) · Journal of Infection · doi:10.1053/jinf.2002.1102 · Cited by 21
Drug interaction of isotretinoin and protease inhibitors: support for the cellular retinoic acid-binding protein-1 theory of lipodystrophy?
Padberg, J., Schürmann, D., Grobusch, M. P., & Bergmann, F. (1999) · AIDS · doi:10.1097/00002030-199902040-00020 · Cited by 21
Anti-IgE and other new immunomodulation-based therapies for allergic asthma.
Jonkers, R. E., & van der Zee, J. S. (2005) · PubMed · Cited by 21
A Review of 685 Rhytidectomies: A New Method of Analysis Based on Digitally Processed Photographs with Computer-Processed Data
Tapia, A., Etxeberria, E., Blanch, A., Laredo, C., & Hamra, S. T. (1999) · Plastic & Reconstructive Surgery · doi:10.1097/00006534-199911000-00031 · Cited by 21
HIV protease inhibitors and atherosclerosis
Hui, D. Y. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17746 · Cited by 21
“Unfortunately, the adverse effects of PIs, including dyslipidemia, lipodystrophy, insulin resistance, and premature atherosclerosis, are cause for concern for their use in chronic management of HIV infection (1, 2).”
Background
Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients
Schwenk, A., Kremer, G., Cornely, O. A., Diehl, V., Fätkenheuer, G., & Salzberger, B. (1999) · Nutrition · doi:10.1016/s0899-9007(99)00083-0 · Cited by 21
Fat Distribution in AIDS
Teplitsky, V., & Halabe, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401218 · Cited by 21
Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead
Jena, R., Vishwas, S., Kumar, R., Kaur, J., Khursheed, R., Gulati, M., Singh, T. G., Vanathi, B. M., Alam, A., Kumar, B., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175173 · Cited by 22
Metabolic syndrome among HIV infected patients: A comparative cross sectional study in northwestern Nigeria
Muhammad, F. Y., Gezawa, I., Uloko, A. E., Yakasai, A. M., Habib, A. G., & Iliyasu, G. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.046 · Cited by 20
Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia
Lum, P. Y., He, Y. D., Slatter, J. G., Waring, J. F., Zelinsky, N., Cavet, G., Dai, X., Fong, O., Gum, R. J., Jin, L., et al. (2007) · Genomics · doi:10.1016/j.ygeno.2007.06.004 · Cited by 20
Nelfinavir Induces Necrosis of 3T3F44-2A Adipocytes by Oxidative Stress
Vincent, S. P., Tourniaire, F., Yazidi, C. M.-E., Compe, E., Manches, O., Plannels, R., & Roche, R. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200412150-00003 · Cited by 20
“Nevertheless, it is now recognized that ;80% of patients receiving highly active antiretroviral treatment develop metabolic abnormalities, which include alterations of glucose and lipid metabolism, insulin resistance, and, sometimes, diabetes mellitus.(7) Clinical symptoms generally include peripheral lipoatrophy, wit…”
Background
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains
Miller, J. F., Furfine, E. S., Hanlon, M. H., Hazen, R. J., Ray, J. A., Robinson, L. H., Samano, V. A., & Spaltenstein, A. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.12.008 · Cited by 20
Management of dyslipidemia in patients with HIV disease
Manfredi, R. (2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00163.x · Cited by 20
Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy
Look, M. P., Riezler, R., Berthold, H. K., Stabler, S. P., Schliefer, K., Allen, R. H., Sauerbruch, T., & Rockstroh, J. ]. K. (2001) · Metabolism · doi:10.1053/meta.2001.27201 · Cited by 20
The Potential of Spirulina platensis to Ameliorate the Adverse Effects of Highly Active Antiretroviral Therapy (HAART)
Sibiya, T., Ghazi, T., & Chuturgoon, A. A. (2022) · Nutrients · doi:10.3390/nu14153076 · Cited by 19
Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
Bonnet, É., Genoux, A., Bernard, J., Fauvel, J., Massip, P., & Perret, B. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.140 · Cited by 19
“It has been proposed that PI might impair normal activation of the RXR-PPARa dimer, resulting in defective down-regulation of apoC-III synthesis and in low apoA-V levels (35).”
Cardiovascular complications in the acquired immunodeficiency syndrome
Bárbaro, G., & da Silva, É. F. R. (2009) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302009000500031 · Cited by 19
Evolution of Resistance Mutations during Low-Level Viral Replication in HIV-1–Infected Patients Treated with Zidovudine/Lamivudine/Abacavir as a First-Line Regimen
Stürmer, M., Dauer, B., Mösch, M., Haberl, A., Mueller, A., Locher, L., Knecht, G., Hanke, N., Doerr, H. W., & Staszewski, S. (2007) · Antiviral Therapy · doi:10.1177/135965350701200102 · Cited by 19
“PI-containing regimens are sometimes more complex and are frequently associated with side-effects such as hyperlipidaemia, insulin resistance or other metabolic abnormalities [11–15].”
Background
Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
ter Hofstede, H. J. M., Burger, D. M., & Koopmans, P. P. (2003) · PubMed · Cited by 19
Calpain-10 (NIDDM1) as a Susceptibility Gene for Common Type 2 Diabetes
Horikawa, Y. (2006) · Endocrine Journal · doi:10.1507/endocrj.kr-70 · Cited by 18
Lipodystrophy in HIV-Infected Pediatric Patients Receiving Protease Inhibitors
Temple, M. E., Koranyi, K. I., & Nahata, M. C. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1a444 · Cited by 19
GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study
Luzi, L., Meneghini, E., Oggionni, S., Tambussi, G., Piceni-Sereni, L., & Lazzarin, A. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02039 · Cited by 19
“Increases in blood lipid level (mainly triglycerides), uric acid concentration and glycemia were all reported with different incidences in populations of HIV-infected patients treated with PIs, NRTIs, NNRTIs or a combination of them (3–6).”
Fat Redistribution in Indinavir-Treated Patients With HIV Infection: A Review of Postmarketing Cases
Benson, J. O., McGhee, K., COPLAN, P. M., Grünfeld, C., Robertson, M. N., Brodovicz, K. G., & Slater, E. E. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200010010-00007 · Cited by 19
Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
Konishi, K., Nakagawa, H., Asaoka, T., Kasamatsu, Y., Goto, T., & Shirano, M. (2022) · Medicine · doi:10.1097/md.0000000000031349 · Cited by 18
“Although there are no reports on hidden obesity in PLWH, abnormalities in the distribution of body fat (increased visceral fat in the abdomen and decreased subcutaneous fat in the limbs and face), called lipoatrophy, have been reported in patients receiving ART for a long period,[15,16] which may be related to the cau…”
Background
Ritonavir-Induced Lipoatrophy and Dyslipidaemia is Reversed by the Anti-Inflammatory Drug Leflunomide in a Ppar-Γ-Dependent Manner
Mencarelli, A., Francisci, D., Renga, B., D’Amore, C., Cipriani, S., Basile, F., Schiaroli, E., Baldelli, F., & Fiorucci, S. (2012) · Antiviral Therapy · doi:10.3851/imp2039 · Cited by 18
“Ritonavir inhibits the activity of insulin-sensitive glucose transporter 4 leading to glucose intolerance and insulin resistance, a condition often associated with central adiposity and hypertrigliceridaemia [3].”
Background
Biological Features Implies Potential Use of Autologous Adipose-Derived Stem/Progenitor Cells in Wound Repair and Regenerations for the Patients with Lipodystrophy
Suzuki, K., Akita, S., Yoshimoto, H., Ohtsuru, A., Hirano, A., & Yamashita, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215505 · Cited by 18
Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection
Burton, C., Nelson, M. R., Hay, P., Gazzard, B., Gotch, F., & Imami, N. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02918.x · Cited by 18
Diabetes and HIV
Quin, J. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-667 · Cited by 18
Severe dyslipidemia and immune activation in HIV patients with dysglycemia
Jin, C., Ji, S., Xie, T., Höxtermann, S., Fuchs, W., Lu, X., Wu, H., Cheng, L., Skaletz‐Rorowski, A., Brockmeyer, N. H., et al. (2016) · HIV Clinical Trials · doi:10.1080/15284336.2016.1207297 · Cited by 18
Overcoming Obstacles to the Success of Protease Inhibitors in Highly Active Antiretroviral Therapy Regimens
Moyle, G. J. (2002) · AIDS Patient Care and STDs · doi:10.1089/108729102761882125 · Cited by 18
HIV‐Associated Facial Lipoatrophy: Establishment of a Validated Grading Scale
Funk, E., Brissett, A. E., Friedman, C. D., & Bressler, F. J. (2007) · The Laryngoscope · doi:10.1097/mlg.0b013e318064e8ab · Cited by 18
Effects of the Human Immunodeficiency Virus-Protease Inhibitor, Ritonavir, on Basal and Catecholamine-Stimulated Lipolysis
Adler‐Wailes, D. C., Liu, H., Ahmad, F., Feng, N., Londos, C., Manganiello, V. C., & Yanovski, J. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2194 · Cited by 18
Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy
Nerurkar, P. V., Shikuma, C. M., & Nerurkar, V. R. (2001) · Clinical Biochemistry · doi:10.1016/s0009-9120(01)00239-9 · Cited by 18
Metabolic and Morphologic Disorders in Patients Treated with Highly Active Antiretroviral Therapy since Primary HIV Infection
Narciso, P., Tozzi, V., D’Offizi, G., Carli, G. D., Orchi, N., Galati, V., Vincenzi, L., Bellagamba, R., Carvelli, C., & Puro, V. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03914.x · Cited by 18
Femtochemie: Studium der Dynamik der chemischen Bindung auf atomarer Skala mit Hilfe ultrakurzer Laserpulse (Nobel-Aufsatz)
Zewail, A. H. (2000) · Angewandte Chemie · doi:10.1002/1521-3757(20000804)112:15 · Cited by 50
Reversal of Hyperlipidemia and Lipodystrophy in Patients Switching Therapy to Nelfinavir
Duncombe, C. J. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200005010-00014 · Cited by 18
Leptin in congenital or HIV-associated lipodystrophy and metabolic syndrome: A need for more mechanistic studies and large, randomized, placebo-controlled trials
Foo, J., & Mantzoros, C. S. (2012) · Metabolism · doi:10.1016/j.metabol.2012.04.013 · Cited by 17
“In PIassociated dyslipidemia, one of the most accepted pathophysiologicalmechanisms is the high affinity of PIs and the catalytic site of the HIV-1 protease, which shares structural homology with two human proteins involved in lipid metabolism i.e. cytoplasmic retinoic-acid binding protein type 1 (CRABP-1) and low den…”
Background
Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
Tetteh, R. A., Nartey, E. T., Lartey, M. Y., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Yankey, B. A., & Dodoo, A. (2016) · Drug Safety · doi:10.1007/s40264-016-0460-7 · Cited by 17
HIV-associated metabolic and morphologic abnormality syndrome
Cohan, G. R. (2000) · Postgraduate Medicine · doi:10.3810/pgm.2000.04.986 · Cited by 17
Potential Interventions for HIV/AIDS Wasting: An Overview
Abrams, D. I. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200010001-00012 · Cited by 17
The metabolic puzzle during the evolution of HIV infection
Salas‐Salvadó, J., & García‐Lorda, P. (2001) · Clinical Nutrition · doi:10.1054/clnu.2001.0429 · Cited by 17
Lack of an Effect of Protease Inhibitor Use on GlucoseTolerance During Pregnancy
Dinsmoor, M. J., & Forrest, S. T. (2002) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1155/s1064744902000212 · Cited by 17
Management of the insulin resistance syndrome
Desouza, C. V., Gilling, L., & Fonseca, V. A. (2001) · Current Diabetes Reports · doi:10.1007/s11892-001-0026-6 · Cited by 17
Fat Redistribution in Indinavir-Treated Patients With HIV Infection: A Review of Postmarketing Cases
Benson, J. O., McGhee, K., COPLAN, P. M., Grünfeld, C., Robertson, M. N., Brodovicz, K. G., & Slater, E. E. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200010010-00007 · Cited by 17
Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance
Kan, V. L., & Nylen, E. S. (1999) · AIDS · doi:10.1097/00002030-199910010-00029 · Cited by 17
Metabolic Abnormalities in HIV Disease and Injection Drug Use
Dobs, A. S., & Brown, T. T. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200210012-00007 · Cited by 17
HIV Lipodystrophy Syndrome: A Primer
Robinson, F. P. (2004) · Journal of the Association of Nurses in AIDS Care · doi:10.1177/1055329003255117 · Cited by 17
Lipid Abnormalities Associated With Protease Inhibitors
Melroe, N. H., Kopaczewski, J., Henry, K., & Huebsch, J. A. (1999) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/s1055-3290(06)60296-3 · Cited by 17
Design, Synthesis, and Structure−Activity Relationships of Novel Insulin Receptor Tyrosine Kinase Activators
Lum, R. T., Cheng, M., Cristobal, C. P., Goldfine, I. D., Evans, J. L., Keck, J., Macsata, R. W., Manchem, V. P., Matsumoto, Y., Park, S. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800600v · Cited by 18
Unusual Distributions of Body Fat in AIDS Patients: A Review of Adverse Events Reported to the Food and Drug Administration
Mann, M., Piazza-Hepp, T. D., Koller, E. A., Struble, K. A., & MURRAY, J. (1999) · AIDS Patient Care and STDs · doi:10.1089/apc.1999.13.287 · Cited by 16
Low serum carnitine in HIV-infected children on antiretroviral treatment
Vilaseca, M. A., Artuch, R., Sierra, C., Pineda, J., López-Vilches, M. A., Muñoz‐Almagro, C., & Fortuny, C. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601694 · Cited by 16
“On the other hand, a syndrome of peripheral lipodystrophy, central adiposity, dyslipidaemia and insulin resistance has been observed in patients treated on protease inhibitors (Carr et al, 1998a).”
Background
Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians
Muhammad, S., Sani, M., & Okeahialam, B. (2013) · Annals of African Medicine · doi:10.4103/1596-3519.108246 · Cited by 16
Centralized Assessment of Dual-Energy X-ray Absorptiometry (DEXA) in Multicenter Studies of HIV-Associated Lipodystrophy
Smith Don, E., Hudson, J., Allison, M., Freund, J., Griffiths Matthew, R., Sue, K., Matthew, L., Andrew, C., Cooper David, A., & for the PIILR DEXA Group and Investigators (2003) · HIV Clinical Trials · doi:10.1310/wrl8-dwh1-7vql-ak81 · Cited by 16
HIV‐1 Infection and the PPAR γ ‐Dependent Control of Adipose Tissue Physiology
Giralt, M., Domingo, P., & Villarroya, F. (2008) · PPAR Research · doi:10.1155/2009/607902 · Cited by 16
“The initial identification of HIV-1 lipodystrophy was coincident with the introduction of drugs from the protease inhibitor family for use in antiretroviral treatment, and these drugs were at first considered to be causative of the syndrome [5].”
Method
Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir
Wilson, M. E., Sengoku, T., & Allred, K. F. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21546 · Cited by 16
“HIV protease inhibitor treatment also causes dyslipidemia that may contribute to the development of cardiovascular disease [Carr et al., 1998].”
Background
Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Filardi, P. P., Paolillo, S., Marciano, C., Iorio, A., Losco, T., Marsico, F., Scala, O., Ruggiero, D., Ferraro, S., & Massimo Chiariello, A. (2008) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152908786786232 · Cited by 16
Complementary and Alternative Therapies to Manage HIV-Related Symptoms
Swanson, B. A., Keithley, J. K., Zeller, J. M., & Cronin‐Stubbs, D. (2000) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/s1055-3290(06)60384-1 · Cited by 16
Strategies for treating HIV-related lipodystrophy
García-Viejo, M. A., Ruíz, M., & Martínez, E. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.8.1443 · Cited by 16
Protease inhibitor therapy and bleeding
Wilde (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00420.x · Cited by 16
Are oral clefts a consequence of maternal hormone imbalance? Evidence from the sex ratios of sibs of probands
James, W. H. (2000) · Teratology · doi:10.1002/1096-9926(200011)62:5 · Cited by 40
Fat redistribution in HIV disease
Rodwell, G. E. J., Maurer, T. A., & Berger, T. G. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104791 · Cited by 16
The impact of human genetic variation on HIV disease in the era of HAART.
Brumme, Z. L., & Harrigan, P. R. (2006) · PubMed · Cited by 16
Protease Inhibitor Effects on Triglyceride Synthesis and Adipokine Secretion in Human Omental and Subcutaneous Adipose Tissue
Cianflone, K., ZAKARIAN, R. J., Stanculescu, C., & Germinario, R. J. (2006) · Antiviral Therapy · doi:10.1177/135965350601100601 · Cited by 16
“Several mechanisms have been proposed for PI action, which invoke multiple protease interference steps (for reviews see [1,46,47]).”
BackgroundInfluential
HIV Protease Inhibitors and Hyperlipidemia
Spector, A. A. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000198749.28422.29 · Cited by 16
Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection
Gedela, K., Vibhuti, M., Pozniak, A., Ward, B., & Boffito, M. (2013) · HIV Medicine · doi:10.1111/hiv.12116 · Cited by 15
Disorders of fat partitioning in treated HIV–infection
Martínez, E. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.10.019 · Cited by 15
The Roles of Genetic Polymorphisms and Human Immunodeficiency Virus Infection in Lipid Metabolism
de Almeida, E. R. D., Reiche, E. M. V., Kallaur, A. P., Flauzino, T., & Watanabe, M. A. E. (2013) · BioMed Research International · doi:10.1155/2013/836790 · Cited by 16
“PIs bind to LRP due to this structural similarity and interfere with LRP-LPL complex formation; as a result, they reduce the adipose storage capacity and increase plasma TG-rich lipoproteins [59].”
Background
Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults.
Freitas, P., Carvalho, D. M., Santos, A. C., Mesquita, J., Correia, F., Xerinda, S., Marques, R., Martínez, E., Sarmento, A., & Medina, J. L. (2011) · PubMed · doi:10.3275/7841 · Cited by 15
Clinical lipoatrophy in HIV‐1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance
Worm, D., Kirk, O., Andersen, O., Vinten, J., Gerstoft, J., Katzenstein, T. L., Nielsen, H. V., & Pedersen, C. D. (2002) · HIV Medicine · doi:10.1046/j.1468-1293.2002.00125.x · Cited by 15
Body composition and lipodystrophy in prepubertal HIV-infected children
Palchetti, C. Z., Patin, R. V., Gouvêa, A. D. F. T. B., Szejnfeld, V. L., Succi, R. C. D. M., & Oliveira, F. L. C. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.12.001 · Cited by 15
Cerebrovascular events in HIV-infected patients: an analysis of a cohort of 3203 HIV+ patients during the times of cART
Arentzen, M., Jubt, F., Evers, S., Heßelmann, V., Fiori, W., Reichelt, D., Oelker-Grueneberg, U., Schwindt, W., Dziewas, R., & Husstedt, I. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.956870 · Cited by 15
“Hyperlipidemia was the most common risk factor and is a well known side effect of cART [43].”
Background
Rat chemokine CXCL11: Structure, tissue distribution, function and expression in cardiac transplantation models
Mitsuhashi, N., Wu, G. D., Zhu, H., Kearns‐Jonker, M., Cramer, D. V., Starnes, V. A., & Barr, M. L. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-9010-9 · Cited by 15
“Moreover, it has been reported that CXCL11 is involved not only in the rejection of vascularized allografts but also acts as a key molecule in many kinds of infectious diseases, various skin diseases, insulitis, arthritis, and encephalomyelitis [47–49].”
Background
Lipid Screening in HIV-Infected Veterans
Korthuis, P. T., Asch, S. M., Anaya, H. D., Morgenstern, H., Goetz, M. B., Yano, E. M., Rubenstein, L. V., Lee, M. L., & Bozzette, S. A. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00005 · Cited by 15
Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals
de Campos, W. R. L., Coopusamy, D., Morris, L., Mayosi, B. M., & Khati, M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01502-08 · Cited by 15
“The severity of mitochondrial toxicity can range from being clinically silent to causing life-threatening conditions such as lactic acidosis (12).”
Background
Coronary Artery Calcium in HIV-infected Men Treated With Highly Active Antiretroviral Therapy
Robinson, F. P., Hoff, J. A., & Kondos, G. T. (2005) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-200505000-00005 · Cited by 15
The Fat Redistribution Syndrome in Patients Infected with HIV
Gerrior, J., Kantaros, J., Coakley, E. P. G., Albrecht, M., & WANKE, C. A. (2001) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(01)00287-5 · Cited by 15
The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling
Cammalleri, C., & Germinario, R. J. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200245-jlr200 · Cited by 15
“many patients on this highly active antiretroviral therapy (HAART) exhibited multiple metabolic perturbations such as altered body fat distribution (1–4) that included peripheral fat atrophy (1, 2) and central adiposity (3, 4).”
Background
Antiretroviral therapy 2000
Samuel, R., & Suh, B. (2000) · Archives of Pharmacal Research · doi:10.1007/bf02976566 · Cited by 15
Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors
de Luis, D. A., Bachiller, P., & Aller, R. (2001) · Nutrition · doi:10.1016/s0899-9007(01)00582-2 · Cited by 15
Initial Therapy with Protease Inhibitor-Sparing Regimens: Evaluation of Nevirapine and Delavirdine
Conway, B. (2000) · Clinical Infectious Diseases · doi:10.1086/313850 · Cited by 15
“A serious discussion of these options is particularly needed in light of recent information that describe the long-term side effects of protease inhibitors, specifically, biochemical abnormalities and lipodystrophy [5, 6].”
Background
A 39-Year-Old Man With HIV-Associated Lipodystrophy
Fuller, J. (2008) · JAMA · doi:10.1001/jama.300.5.jrr80007 · Cited by 14
Screening and management of cardiovascular disease in Australian adults with HIV infection
Chan, D. J., Gracey, D. M., Bailey, M., Richards, D., & Dalton, B. S. (2013) · Sexual Health · doi:10.1071/sh13009 · Cited by 14
Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
Hiransuthikul, N., Hiransuthikul, P., & Kanasook, Y. (2007) · PubMed · Cited by 14
Managing HIV lipoatrophy
Moyle, G. J., & Sutinen, J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15521-9 · Cited by 14
Objective evidence for the use of polylactic acid implants in HIV-associated facial lipoatrophy using three-dimensional surface laser scanning and psychological assessment
Ong, J., Clarke, A. M., White, P., Johnson, M. A., Withey, S., & Butler, P. E. M. (2008) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2008.07.046 · Cited by 14
Serum l-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers
ter Hofstede, H. J. M., Willems, H. L., & Koopmans, P. P. (2003) · Journal of Clinical Virology · doi:10.1016/s1386-6532(03)00085-4 · Cited by 14
Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors
Lee, G. A., Rao, M. N., & Grünfeld, C. (2006) · American Journal of Infectious Diseases · doi:10.3844/ajidsp.2006.159.166 · Cited by 14
Progression of Lipodystrophy (LD) with Continued Thymidine Analogue Usage: Long-Term Follow-Up from a Randomized Clinical Trial (The PIILR Study)
Martin, A. M., Smith, D. E., Carr, A. D., Hoy, J., Chuah, J., Mallal, S. A., Law, M. G., Clements, M., Cooper, D. A., & for the PIILR study group (2004) · HIV Clinical Trials · doi:10.1310/0gu7-6x27-mmhe-5ale · Cited by 14
Self-citation
Nail, hair and skin hyperpigmentation associated with indinavir therapy
Terheggen, F., Frissen, J., Weigel, H. M., Schouten, I., & Brinkman, K. (2004) · AIDS · doi:10.1097/01.aids.0000131370.90575.48 · Cited by 14
Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol
Salazar, J., Guardiola, M., Ferré, R., Coll, B., Alonso‐Villaverde, C., Winklhofer‐Roob, B. M., Rock, E., Fernandez-Ballart, J. D., Civeira, F., Pocovı́, M., et al. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.131 · Cited by 14
Lipemia Retinalis in Acquired Immunodeficiency Syndrome Treated With Protease Inhibitors
Eng, K. T., Liu, E. S., Silverman, M. S., & Berger, A. R. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.3.425 · Cited by 14

Authors: Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A.
Affiliations: UNSW Sydney (AU)
Garvan Institute of Medical Research (AU)
Corresponding author: Carr, Andrew
ORCID: Samaras, Katherine
Chisholm, Donald J
Venue: The Lancet
Publisher: Elsevier BV
Published: 1998-06
Volume: 351
Issue: 9119
Pages: 1881-1883
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(98)03391-1
OpenAlex: W2171030070
Cited by: 1,065
References: 24
Citations by year: 2026: 2 · 2025: 3 · 2024: 12 · 2023: 2 · 2022: 12 · 2021: 7 · 2020: 10 · 2019: 16 · 2018: 15 · 2017: 18 · 2016: 15 · 2015: 18 · 2014: 17 · 2013: 30 · 2012: 23
FWCI: 143.69
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council
National Medical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords: HIV-1 protease inhibitors, hyperlipidemia, insulin resistance, abdominal obesity, breast hypertrophy, LRP, retinoic acid synthesis, retinoid X receptor, PPARγ, adipogenesis, adipocyte apoptosis, lipoprotein lipase, type 2 diabetes
MeSH terms: Cytochrome P-450 Enzyme System, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Insulin Resistance, Lipodystrophy, Obesity, Receptors, Immunologic, HIV Protease Inhibitors, Sequence Homology, Amino Acid, Receptors, Retinoic Acid, Low Density Lipoprotein Receptor-Related Protein-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks